Evoke Pharma (NASDAQ:EVOK) Coverage Initiated by Analysts at StockNews.com

Investment analysts at StockNews.com started coverage on shares of Evoke Pharma (NASDAQ:EVOK) in a research note issued on Wednesday. The firm set a “sell” rating on the specialty pharmaceutical company’s stock.

Evoke Pharma Trading Down 1.1 %

EVOK stock opened at $4.46 on Wednesday. Evoke Pharma has a 1-year low of $3.54 and a 1-year high of $12.32. The firm has a market cap of $6.63 million, a P/E ratio of -0.41 and a beta of 0.15. The business’s 50 day moving average is $4.57 and its 200-day moving average is $5.07.

Institutional Investors Weigh In On Evoke Pharma

An institutional investor recently bought a new position in Evoke Pharma stock. Corsair Capital Management L.P. acquired a new stake in Evoke Pharma, Inc. (NASDAQ:EVOK) during the third quarter, according to its most recent filing with the SEC. The firm acquired 11,667 shares of the specialty pharmaceutical company’s stock, valued at approximately $56,000. Corsair Capital Management L.P. owned about 1.42% of Evoke Pharma as of its most recent filing with the SEC.

About Evoke Pharma

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.